Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221027086> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4221027086 abstract "Abstract Background: Many patients with incurable esophageal cancer (ECa) present with dysphagia as their predominant symptom. Currently there is no consensus on how best to initially manage this scenario with multiple therapeutic options available. We aimed to assess the safety and efficacy of using hypofractionated radiotherapy given over a progressively shorter timeframe with concurrent carboplatin and paclitaxel in the management of patients with ECa and dysphagia. Methods: In this phase I trial we enrolled patients with histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus or the gastro-esophageal junction with symptomatic dysphagia from local disease and not for curative treatment. Patients needed to be 18 years or older, have an ECOG performance status of 0-2 and be suitable to receive carboplatin and paclitaxel chemotherapy. Patients were placed in four progressively shorter radiation schedules culminating in 30Gy in 10 fractions in a step wise manner, all with concurrent carboplatin AUC 2 and paclitaxel 50mg/m 2 chemotherapy delivered weekly with the radiation therapy. The primary endpoint was the development of the dose limiting toxicities (DLTs) esophageal perforation or febrile neutropenia. Secondary endpoints were relief of dysphagia, time to improvement of dysphagia, dysphagia progression free survival and overall survival. Results: Eighteen patients were enrolled in the study between October 2014 and March 2019. There were no DLTs experienced during the trial. The most common grade 3+ acute toxicity experienced by patients were nausea and vomiting (both in 4/18 patients). The most common radiation specific acute toxicity experienced was esophagitis with 67% of patients experiencing grade 1-2 symptoms. All patients experienced improvement in dysphagia. The median time to dysphagia improvement was three weeks from the start of chemoradiotherapy (CTRT) (range 2-10 weeks). The median dysphagia free survival was 5.8 months with a median overall survival of 8.9 months. Conclusion: Hypofractionated palliative CTRT with 30Gy/10# of radiation therapy with concurrent weekly carboplatin and paclitaxel chemotherapy is well tolerated and provides a good response in improvement of dysphagia. Further studies need to be undertaken which provide both symptomatic improvement in the primary tumor but also control of the metastatic burden in these patients. Clinical Trial Registration: This trial was prospectively registered with www.anzctr.org.au Identifier: ACTRN12614000821695" @default.
- W4221027086 created "2022-04-03" @default.
- W4221027086 creator A5002098356 @default.
- W4221027086 creator A5017507076 @default.
- W4221027086 creator A5019829841 @default.
- W4221027086 creator A5022097331 @default.
- W4221027086 creator A5031174887 @default.
- W4221027086 creator A5037268581 @default.
- W4221027086 creator A5054407826 @default.
- W4221027086 creator A5056940320 @default.
- W4221027086 creator A5071952878 @default.
- W4221027086 creator A5086079214 @default.
- W4221027086 date "2022-03-22" @default.
- W4221027086 modified "2023-09-25" @default.
- W4221027086 title "Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer" @default.
- W4221027086 doi "https://doi.org/10.21203/rs.3.rs-1463635/v1" @default.
- W4221027086 hasPublicationYear "2022" @default.
- W4221027086 type Work @default.
- W4221027086 citedByCount "0" @default.
- W4221027086 crossrefType "posted-content" @default.
- W4221027086 hasAuthorship W4221027086A5002098356 @default.
- W4221027086 hasAuthorship W4221027086A5017507076 @default.
- W4221027086 hasAuthorship W4221027086A5019829841 @default.
- W4221027086 hasAuthorship W4221027086A5022097331 @default.
- W4221027086 hasAuthorship W4221027086A5031174887 @default.
- W4221027086 hasAuthorship W4221027086A5037268581 @default.
- W4221027086 hasAuthorship W4221027086A5054407826 @default.
- W4221027086 hasAuthorship W4221027086A5056940320 @default.
- W4221027086 hasAuthorship W4221027086A5071952878 @default.
- W4221027086 hasAuthorship W4221027086A5086079214 @default.
- W4221027086 hasBestOaLocation W42210270861 @default.
- W4221027086 hasConcept C121608353 @default.
- W4221027086 hasConcept C126322002 @default.
- W4221027086 hasConcept C141071460 @default.
- W4221027086 hasConcept C143998085 @default.
- W4221027086 hasConcept C203092338 @default.
- W4221027086 hasConcept C2776694085 @default.
- W4221027086 hasConcept C2777819096 @default.
- W4221027086 hasConcept C2778239845 @default.
- W4221027086 hasConcept C2778424827 @default.
- W4221027086 hasConcept C2779134260 @default.
- W4221027086 hasConcept C2779742542 @default.
- W4221027086 hasConcept C2779920096 @default.
- W4221027086 hasConcept C2780580376 @default.
- W4221027086 hasConcept C2780596822 @default.
- W4221027086 hasConcept C2780852908 @default.
- W4221027086 hasConcept C2781451048 @default.
- W4221027086 hasConcept C43270747 @default.
- W4221027086 hasConcept C509974204 @default.
- W4221027086 hasConcept C535046627 @default.
- W4221027086 hasConcept C71924100 @default.
- W4221027086 hasConceptScore W4221027086C121608353 @default.
- W4221027086 hasConceptScore W4221027086C126322002 @default.
- W4221027086 hasConceptScore W4221027086C141071460 @default.
- W4221027086 hasConceptScore W4221027086C143998085 @default.
- W4221027086 hasConceptScore W4221027086C203092338 @default.
- W4221027086 hasConceptScore W4221027086C2776694085 @default.
- W4221027086 hasConceptScore W4221027086C2777819096 @default.
- W4221027086 hasConceptScore W4221027086C2778239845 @default.
- W4221027086 hasConceptScore W4221027086C2778424827 @default.
- W4221027086 hasConceptScore W4221027086C2779134260 @default.
- W4221027086 hasConceptScore W4221027086C2779742542 @default.
- W4221027086 hasConceptScore W4221027086C2779920096 @default.
- W4221027086 hasConceptScore W4221027086C2780580376 @default.
- W4221027086 hasConceptScore W4221027086C2780596822 @default.
- W4221027086 hasConceptScore W4221027086C2780852908 @default.
- W4221027086 hasConceptScore W4221027086C2781451048 @default.
- W4221027086 hasConceptScore W4221027086C43270747 @default.
- W4221027086 hasConceptScore W4221027086C509974204 @default.
- W4221027086 hasConceptScore W4221027086C535046627 @default.
- W4221027086 hasConceptScore W4221027086C71924100 @default.
- W4221027086 hasLocation W42210270861 @default.
- W4221027086 hasOpenAccess W4221027086 @default.
- W4221027086 hasPrimaryLocation W42210270861 @default.
- W4221027086 hasRelatedWork W1499151 @default.
- W4221027086 hasRelatedWork W184216 @default.
- W4221027086 hasRelatedWork W2548310 @default.
- W4221027086 hasRelatedWork W2942244 @default.
- W4221027086 hasRelatedWork W32134210 @default.
- W4221027086 hasRelatedWork W3582852 @default.
- W4221027086 hasRelatedWork W370487 @default.
- W4221027086 hasRelatedWork W4429043 @default.
- W4221027086 hasRelatedWork W4467696 @default.
- W4221027086 hasRelatedWork W964261 @default.
- W4221027086 isParatext "false" @default.
- W4221027086 isRetracted "false" @default.
- W4221027086 workType "article" @default.